(1 day, 18 hours ago)
Commons ChamberMy hon. Friend is absolutely right. We need to ensure that the new measures are implemented. As I say, I do not want to undermine confidence in that, because I do not want to give anybody a get-out clause for not implementing them. We will be working over the next few weeks with both the BPI and the Association of Independent Music on putting together a proper evaluation process over the next year, and I hope I will be making a statement in a year’s time—although obviously that will not be up to me—on precisely how it has worked out. As I said earlier, I reckon this is worth several tens of millions of pounds of extra investment in the British music industry, and I think we will see that it has delivered.
Just returning to the issue of my tie, Madam Deputy Speaker: it is a Day of the Dead tie by Van Buck.
The Minister does very well to shake off the abuse about his tie from the Swiftie on the Opposition Benches—it is mainly empty spaces there—the right hon. Member for New Forest East (Sir Julian Lewis). His reputation remains unscathed.
Calder Valley has a thriving creative sector with lots of small and independent artists who have lost out to streaming. Today’s announcement is welcome, of course, but small artists face the twin threat of both AI and streaming. Will the Minister assure me and the House that he will do more to ensure that those small artists can get the money in their pockets, where it belongs?
The point I made about the remuneration of musicians, and all forms of artists, applies equally to streaming and to AI. The Secretaries of State for Culture, Media and Sport and for Science, Innovation and Technology held their first meeting last week with the creative industries and AI companies to discuss how we proceed on the issue of AI and copyright. There is a broadly outlined set of principles, one of which is undoubtedly that those who made the original work must be remunerated when it is used to create some other form of work and some other form of value.
I agree with my hon. Friend on his point about empty spaces on the Opposition Benches—empty chairs at empty tables.
(5 months, 2 weeks ago)
Commons ChamberUrgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
It is not entirely dependent on our AstraZeneca programme, and indeed, as I have already pointed out, the piece of work in which it was intending to invest—I hope I will get the science right—was changing the way in which it would create the nasal flu vaccine for children from an egg-based to a cell-based system. It has now decided not to do that, but to stick to the egg-based system. I think that if the chief scientific adviser or the chief medical officer has anything on which to update the House, he and/or she will do so.
Despite AstraZeneca’s decision, the UK biotech industry almost doubled last year to £3.4 billion, but it was concentrated in just a few companies. Will the Minister commit to looking at some of the trial research rules to enable smaller companies to work better with NHS trusts so that start-ups and local firms can prosper?
My hon. Friend is right: not only do we need to enable smaller companies to start up, but we need to enable them to grow to scale. Otherwise, the danger is that we develop the good idea, someone else ends up buying the intellectual property, and all the value disappears out the UK’s back door. When I met the husband-and-wife team who run BioNtech—they are amazing, not least in respect of some of the work they have done in developing immunotherapy, which is probably the stuff that saved my life when I had stage 4 cancer—they spoke warmly and glowingly about all the work that they want to do in the UK, alongside the work of AstraZeneca. As my hon. Friend says, we need to get small companies set up, to grow them, and to enable them to be world leaders like AstraZeneca.